<DOC>
	<DOC>NCT02372006</DOC>
	<brief_summary>Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2. Biomarker specific MTD expansion cohort to assess clinical anti-tumour activity in included tumour types</brief_summary>
	<brief_title>Phase I Trial of Afatinib in Pediatric Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<criteria>Inclusion criteria: Paediatric patients aged 2 years to &lt;18 years at the time of informed consent diagnosis of HGG, DIPG, low grade astrocytoma, medulloblastoma/PNET, ependymoma, neuroblastoma, RMS and tumours with ErbB deregulation recurrent/refractory disease after they received at least one prior standard treatment regimen no effective conventional therapy exists Performance status &gt;= 50% (Lansky for =&lt;12ys; Karnofsky for &gt;12ys) Exclusion criteria: relevant toxicity from previous treatment known preexisting relevant cardiac , hepatic, renal, bone marrow dysfunction, ILD, keratitis</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>